Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Immunocore Holdings plcNASDAQ: IMCR

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $946.41K rose 10.8% year over year, ahead of the -22.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 53.1% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.

Context

  • Depreciation & amortization amounted to 0.8% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +10.8% holds above the trailing-twelve-month pace of -22.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$946.41K+53.1% QoQ
Last fiscal yearDec 2025
$2.43M-27.6% YoY
LTMMar 2026
$3.14M-22.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.8%——
1 year-27.6%——
3-year CAGR-18.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

Mixed currencies · from the income statement

Latest · FY2025
2.43M USD
Year-over-year change
-27.6%

Depreciation & Amortization vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -22.4% is the lowest of 10, against a peer median of +0.0%.
  • Depreciation & amortization amounts to 0.8% of revenue for IMCR, versus a peer median of 9.5%.
IMCR Competitors
Depreciation & Amortization for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€676.85M EUR+122.9%+43.9%25.6%
IBRXImmunityBio, Inc.LTM Sep 2026$16.54M USD+4.6%-5.3%9.1%
IMTXImmatics N.V.LTM Mar 2026€12.04M EUR-2.6%+21.9%32.3%
XNCRXencor, Inc.LTM Jun 2026$10.17M USD-10.7%+6.1%9.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026$10M USD+0.0%+18.6%8.5%
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M USD-5.1%-15.4%4.5%
IPHAInnate Pharma S.A.FY2025€5.09M EUR+155.3%-51.8%182.7%
IMCRImmunocore Holdings plcLTM Mar 2026$3.14M USD-22.4%-18.0%0.8%
IMMPImmutep LimitedFY2025A$2.13M AUD+6.0%+5.1%42.3%
JANXJanux Therapeutics, Inc.LTM Mar 2026$2.03M USD-0.8%+34.1%9.4%
CGENCompugen Ltd.LTM Mar 2026$0 USD—-0.5%0.0%
Peer median (excluding IMCR) —+0.0%+5.6%9.5%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.